Actively Recruiting
Multicenter Randomized Study of VER-01 Cannabis Extract Versus Placebo for Chronic Painful Lumbosacral Radiculopathy
Led by Vertanical GmbH · Updated on 2026-11-02
810
Participants Needed
32
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of VER-01, a full-spectrum cannabis extract, in adults with chronic painful lumbosacral radiculopathy who have not achieved sufficient pain relief from non-opioid analgesics or cannot use them due to contraindications or intolerance. This phase 3, randomized, double-blind, placebo-controlled trial aims to compare VER-01 to placebo in reducing pain over 12 weeks. The study is sponsored by Vertanical GmbH and uses a parallel design with multiple arms. Participants will be randomly assigned to receive one of two doses of VER-01 or a placebo. VER-01 is a standardized soft extract from Cannabis sativa containing 19 mg of 9-Tetrahydrocannabinol THC per ml. The study lasts 12 weeks of treatment, during which participants will follow a treatment plan, attend scheduled visits, and record information in an electronic diary. The trial includes careful monitoring of safety and efficacy throughout the treatment period. Participants will be involved in scheduled visits and required to comply with the treatment plan and use of an electronic diary. Researchers will assess pain reduction from baseline to week 12 as the primary outcome. Safety evaluations will monitor for any adverse effects. The total participation duration covers the 12-week treatment period, with assessments focused on pain relief and treatment tolerability.
CONDITIONS
Brief Title
Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy
Research Team
V
Vertanical GmbH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here